Nandrolone with testosterone

There are possible estrogenic side effects of Nandrolone despite it not being a very estrogenic hormone, at least not directly. Nandrolone does aromatize slightly. Aromatization refers to the conversion of testosterone to estrogen . This takes place when the testosterone hormone interacts with the aromatase enzyme. When the conversion takes place this can cause estrogen levels to go up, which can promote gynecomastia and water retention. High blood pressure can also become an issue if water retention becomes severe. Along with the low level of aromatase activity Nandrolone is also a progestin and has a strong binding affinity for the progesterone receptor. This may stimulate the mammary tissue and enhance the risk of gynecomastia in sensitive individuals.

Combating the estrogenic side effects of Nandrolone can be achieved by the use of anti-estrogen medications, specifically Aromatase Inhibitors (AI’s) such as Anastrozole ( Arimidex ). Selective Estrogen Receptor Modulators (SERM’s) are also sometimes used, such as Tamoxifen ( Nolvadex ). However, AI’s are the proper choice as they will directly reduce serum estrogen levels and SERM’s will not. An AI should be enough to reduce and avoid gynecomastia unless the individual already has existing gynecomastia that could potentially be exasperated.

Important Note: It’s often been said that Nandrolone based gynecomastia is based on increases in prolactin. It is true that 19-nor steroids can increase prolactin, which can also negatively affect libido and erection function. Some men may need to use a dopamine agonist to combat this. However, it is not prolactin that causes 19-nor based gynecomastia but rather the imbalance between estrogen and progesterone. If you merely combat prolactin you may find yourself with the very gynecomastia you tried to avoid.
 

After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol. [26] In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism . [27] After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .

Nandrolone with testosterone

nandrolone with testosterone

Media:

nandrolone with testosteronenandrolone with testosteronenandrolone with testosteronenandrolone with testosteronenandrolone with testosterone

http://buy-steroids.org